What are the latest updates to adult small cell lung cancer treatment, including first‑line platinum‑etoposide plus PD‑L1 inhibitor regimens, maintenance durvalumab after concurrent chemoradiation, and second‑line chemotherapy options?

Latest Updates in Small Cell Lung Cancer Treatment

The most significant recent advance is FDA approval of tarlatamab, a bispecific T-cell engager, for relapsed SCLC after at least two prior systemic regimens, offering a 40% response rate with a remarkable 9.7-month median duration of response—substantially longer than other available agents. 1

First-Line Treatment for Extensive-Stage SCLC

Standard of Care: Platinum-Etoposide Plus PD-L1 Inhibitor

Both atezolizumab and durvalumab combined with platinum-etoposide are established first-line standards of care for extensive-stage SCLC. 2, 3

• Durvalumab plus platinum-etoposide demonstrates sustained overall survival benefit with median OS of 12.9 months versus 10.5 months for chemotherapy alone (HR 0.75, p=0.0032) 3
• The regimen consists of 4 cycles of durvalumab 1500 mg plus carboplatin/cisplatin and etoposide every 3 weeks, followed by maintenance durvalumab 1500 mg every 4 weeks until progression 3
• Atezolizumab plus carboplatin-etoposide similarly prolongs OS and PFS without adversely impacting quality of life 2
• Real-world data show comparable efficacy between atezolizumab and durvalumab regimens, with both well-tolerated in clinical practice 4

Important Note on Triple Therapy

Adding tremelimumab to durvalumab plus platinum-etoposide does NOT significantly improve outcomes (HR 0.82, p=0.045, not meeting significance threshold) and increases toxicity, including higher treatment-related death rates (5% vs 2% with durvalumab alone) 3

Limited-Stage SCLC: Consolidation Immunotherapy

Patients with limited-stage SCLC who complete concurrent chemoradiotherapy without progression should receive consolidation durvalumab for up to 2 years (strong recommendation, moderate evidence quality) 1

• This applies even to patients with ECOG PS 3-4 if their performance status improves after chemoradiation (conditional recommendation, low evidence quality) 1
• Contraindications to immunotherapy must be excluded before initiating consolidation 1

Relapsed/Refractory SCLC: Major Therapeutic Advances

Chemotherapy-Free Interval <90 Days (Platinum-Resistant)

Single-agent systemic therapy is preferred over multiagent regimens due to better risk-benefit balance. 1 The three FDA-approved preferred agents are:

1. Tarlatamab (newest option, 2024-2025)

   • Bispecific T-cell engager targeting DLL3 on SCLC cells and CD3 on T cells 1
   • Dosing regimen: 1 mg IV on day 1 of cycle 1, then 10 mg on days 8 and 15 of cycle 1, then 10 mg every 2 weeks thereafter 1
   • 40% overall response rate with 9.7-month median duration of response 1
   • Particularly effective in platinum-resistant disease (52% response rate) 1
   • Critical safety consideration: Requires 24-hour inpatient monitoring after first two doses (days 1 and 8 of cycle 1) for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) 1
   • CRS occurs in 51% (mostly grade 1-2, median onset 13 hours, median duration 4 days, nearly all in cycle 1) 1
   • ICANS occurs in 8% (all grade 1-2) 1
   • Exclusion criteria: Interstitial lung disease, active pneumonitis, grade ≥2 pneumonitis from prior immunotherapy 1

2. Lurbinectedin

   • Cross-trial comparisons suggest superior efficacy to topotecan 1

3. Topotecan

   • Historically standard option 1

Chemotherapy-Free Interval ≥90 Days (Platinum-Sensitive)

Either rechallenge with platinum-based regimen OR single-agent systemic therapy may be offered (moderate evidence quality, strong recommendation) 1

Key Clinical Pitfalls to Avoid

• Do not add tremelimumab to durvalumab-platinum-etoposide in first-line ES-SCLC—it increases toxicity without survival benefit 3
• Do not skip inpatient monitoring for the first two tarlatamab doses; CRS occurs in over half of patients, though severe cases are rare 1
• Screen carefully for contraindications before tarlatamab: patients with active pneumonitis, interstitial lung disease, or grade ≥2 prior immune-related pneumonitis should be excluded 1
• Sequencing of relapsed agents remains undefined—the DeLLphi-304 trial comparing tarlatamab to standard chemotherapy is ongoing to guide optimal sequencing 1

Comparative Efficacy in Relapsed Setting

Tarlatamab demonstrates the longest duration of response (>9 months) compared to other relapsed SCLC agents, though direct head-to-head comparisons are lacking 1. The 9-month PFS and OS rates with tarlatamab are 28% and 68%, respectively, representing meaningful long-term disease control in a heavily pretreated population (73% had prior immunotherapy) 1.